English
Home > Products > Nebivolol API

China Nebivolol API Factory

We also offer you product sourcing and flight consolidation expert services. We've our personal manufacturing unit and sourcing business. We can offer you virtually every variety of merchandise associated to our item range for Nebivolol API,CAS NO 152520-56-4,152520-56-4,Nebivolol hydrochloride, Never-ending improvement and striving for 0% deficiency are our two main quality policies. Should you need anything, don't hesitate to contact us.
Nebivolol API, If you have any requests, pls email Us with your detailed demands, we are going to offer you the most wholesale Competitive Price with the Super Quality and the Unbeatable First-class Service ! We can offer you the most competitive prices and high quality, because we have been much more Skilled! So remember to do not hesitate to contact us.

Related Products

Hot Products

  • Ethyl 2-methylacetoacetate

    Ethyl 2-methylacetoacetate

    Product Name:Ethyl 2-methylacetoacetate
    Molecular Formula:C7H12O3
    Molecular Weight:144.17
    CAS Registry Number:609-14-3
  • N-blocked-5'-O-DMT-2'-O-TBDMS CED cytidine phosphoramidite

    N-blocked-5'-O-DMT-2'-O-TBDMS CED cytidine phosphoramidite

    Product Name:N-blocked-5'-O-DMT-2'-O-TBDMS CED cytidine phosphoramidite
    Molecular Formula:C52H66N5O9PSi
    Molecular Weight:964.17
    CAS Registry Number:118380-84-0
  • Amlexanox

    Amlexanox

    Product Name:Amlexanox
    Molecular Formula:C16H14N2O4
    Molecular Weight;298.29
    CAS Registry Number;68302-57-8
  • Etonogestrel

    Etonogestrel

    Product Name:Etonogestrel
    Molecular Formula:C22H28O2
    Molecular Weight:324.46
    CAS Registry Number;54048-10-1
  • Losartan potassium

    Losartan potassium

    Product Name:Losartan potassium
    Molecular Formula:C22H23ClKN6O
    Molecular Weight;462.01
    CAS Registry Number;124750-99-8
  • Delafloxacin

    Delafloxacin

    Product Name:Delafloxacin
    Molecular Formula:C24H23F3N4O5
    Molecular Weight;504.46
    CAS Registry Number;442526-91-2
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept